Aaron Prodeus
YOU?
Author Swipe
View article: A differentiated and durable allogeneic strategy applicable to cell therapies
A differentiated and durable allogeneic strategy applicable to cell therapies Open
Autologous T cell therapies have shown profound clinical responses; however, their widespread use has been limited primarily due to their individualized manufacturing requirements. To develop a persistent "off-the-shelf" allogeneic (Allo) …
View article: 342 Improving TCR-T cell function against solid tumors with immune enhancing edits
342 Improving TCR-T cell function against solid tumors with immune enhancing edits Open
Background The success of T cell therapies for the treatment of solid tumors has been limited. Factors limiting efficacy in solid tumors are poor infiltration, exhaustion, and an immunosuppressive tumor microenvironment (TME). Methods To a…
View article: Can CD200R1 Agonists Slow the Progression of Osteoarthritis Secondary to Injury?
Can CD200R1 Agonists Slow the Progression of Osteoarthritis Secondary to Injury? Open
Post-traumatic knee osteoarthritis is characterized by cartilage degeneration, subchondral bone remodeling, osteophyte formation, and synovial changes. Therapeutic targeting of inflammatory activity in the knee immediately post injury may …
View article: CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function
CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function Open
T cell receptor (TCR)–based therapy has the potential to induce durable clinical responses in patients with cancer by targeting intracellular tumor antigens with high sensitivity and by promoting T cell survival. However, the need for TCRs…
View article: Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity
Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity Open
Canadian Institutes of Health Research (no. 148556).
View article: A Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In Vivo
A Synthetic Cross-Species CD200R1 Agonist Suppresses Inflammatory Immune Responses In Vivo Open
Functional aptamers displaying agonistic or antagonistic properties are showing great promise as modulators of immune responses. Here, we report the development of a polyethylene glycol-modified (PEGylated) DNA aptamer as a cross-species (…
View article: Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni Syndrome
Association Between the Oligomeric Status of p53 and Clinical Outcomes in Li-Fraumeni Syndrome Open
Li-Fraumeni syndrome (LFS) is a rare hereditary cancer disorder with highly variable clinical outcomes that results from germline mutations in the TP53 gene. Here we report that the quaternary structure of p53 is an important factor affect…
View article: VISTA.COMP — an engineered checkpoint receptor agonist that potently suppresses T cell–mediated immune responses
VISTA.COMP — an engineered checkpoint receptor agonist that potently suppresses T cell–mediated immune responses Open
V-domain immunoglobulin suppressor of T cell activation (VISTA) is a recently discovered immune checkpoint ligand that functions to suppress T cell activity. The therapeutic potential of activating this immune checkpoint pathway to reduce …
View article: p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis
p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis Open
Mutations in the oligomerization domain of p53 are genetically linked to cancer susceptibility in Li-Fraumeni Syndrome. These mutations typically alter the oligomeric state of p53 and impair its transcriptional activity. Activation of p53 …
View article: p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis
p53 oligomerization status modulates cell fate decisions between growth, arrest and apoptosis Open
Mutations in the oligomerization domain of p53 are genetically linked to cancer susceptibility in Li-Fraumeni Syndrome. These mutations typically alter the oligomeric state of p53 and impair its transcriptional activity. Activation of p53 …